Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?
Increased reports of mumps in vaccinated populations prompted a review of the performance of mumps vaccines. The effectiveness of prior vaccination with 1 dose of vaccine ranged from 72.8% to 91% for the Jeryl Lynn strain, from 54.4% to 93% for the Urabe strain, and from 0% to 33% for the Rubini strain. Vaccine effectiveness after 2 doses of mumps vaccine was reported in 3 outbreaks and ranged from 91% to 94.6%. There was evidence of waning immunity, which is a likely factor in mumps outbreaks, aggravated by possible antigenic differences between the vaccine strain and outbreak strains. Inadequate vaccine coverage or use of the Rubini vaccine strain accounted for the majority of outbreaks reviewed; however, some outbreaks could not be prevented, despite high vaccination coverage with 2 doses of the Jeryl Lynn vaccine strain. Our findings indicate the need for more-effective mumps vaccines and/or for review of current vaccination policies to prevent future outbreaks.
Dayan
Gustavo H
GH
Clinical Department, Sanofi Pasteur, Swiftwater, Pennsylvania, USA.
Rubin
Steven
S
D004196:Disease Outbreaks; D006801:Humans; D015994:Incidence; D009107:Mumps / Q000453:epidemiology* / Q000276:immunology*; D009108:Mumps Vaccine / Q000008:administration & dosage / Q000276:immunology*; D019213:Rubulavirus / Q000276:immunology / Q000302:isolation & purification
D009108:Mumps Vaccine